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26 
Introduction 27 
Population screening programmes for colorectal cancer (CRC) vary 28 
worldwide[1], although the commonest approach is to test stool samples for 29 
small amounts of blood (or its degradation products) – fecal occult blood 30 
testing (FOBt)[2]. Meta-analysis of 4 randomized trials which enrolled over 31 
300,000 participants estimated the reduction in CRC mortality at 32 
approximately 16%[3]. Individuals who test FOBt-positive require further 33 
testing to confirm or refute the presence of neoplasia: Approximately 50% will 34 
have CRC or adenoma(s)[4]. The main target lesion of screening is termed 35 
advanced neoplasia, corresponding to CRC or an “advanced adenoma” 36 
(which itself is defined as an adenoma measuring ≥10mm or demonstrating 37 
high-grade dysplasia or >20% villous histology)[5]. When screening with 38 
FOBt, it is common practice to use a test kit with two separate windows in 39 
which to place the stool sample and to repeat the test on three occasions, 40 
yielding six separate results[6]. A “positive test” may therefore vary from only 41 
a single window to all six being positive. This variability influences the positive 42 
predictive value (PPV) for CRC, which ranged from 1% to 6% in the 43 
Minnesota randomised trial of FOBt screening, increasing with each additional 44 
positive window[7]. More recent observational studies have confirmed this, 45 
although generally with higher rates of CRC for a given number of positive 46 
FOBt windows[8,9]. 47 
 48 
 49 
For most screenees, colonoscopy is the preferred test following positive FOBt, 50 
since it combines diagnosis with treatment by excision biopsy for smaller 51 
cancers and adenomas. However, a proportion of screening participants are 52 
unable to undergo total colonoscopy due to frailty, refusal or technical failure. 53 
CT colonography (CTC) is a well-tolerated alternative, with sensitivity for 54 
≥6mm adenomas or CRC estimated at 89% by meta-analysis[10]. CTC 55 
diagnostic yield of CRC and adenomas has rarely been reported following a 56 
positive FOBt result on a population level, with one retrospective 57 
observational study reporting detection rates of 4.5% for CRC and 13.9% for 58 
advanced adenomas in patients judged relatively unsuitable for 59 
colonoscopy[11]. These detection rates were approximately 50% lower than 60 
for colonoscopy, although whether this was due to selection bias (i.e. higher 61 
incidence of false positive FOBt in patients undergoing CTC) or lower 62 
sensitivity of CTC is unknown. Furthermore, the outcome of CTC according to 63 
the number of positive FOBt windows was not reported. We are not aware of 64 
any data regarding this for CTC. Here, we report detection rates of CRC and 65 
advanced neoplasia at CTC stratified by FOBt positivity. 66 
 67 
 68 
Materials and Methods 69 
A waiver to publish anonymized data was obtained from our institution’s 70 
research office. Data were collated from the English national Bowel Cancer 71 
Screening Programme (BCSP)[4]. English residents aged 60-74 years are 72 
invited to complete and return a postal guaiac FOBt kit to one of five regional 73 
laboratories (“screening hubs”). Individuals testing positive are invited for 74 
consultation at one of 58 “screening centres”. Positive FOBt results can be 75 
stratified by the number of positive windows. If the initial test kit shows 5-6 76 
positive windows, the result is deemed a “strong positive” and further colonic 77 
testing is immediately recommended. Alternatively, if 1-4 windows are 78 
positive, the test is repeated twice: If either subsequent kit shows any positive 79 
windows, the patient is categorized as having a “weak positive” FOBt result 80 
overall (irrespective of the number of positive windows on the follow-up kits). 81 
In either case (weak or strong positive), consenting individuals are referred for 82 
colonoscopy: Those deemed unsuitable are either discharged from the 83 
programme or referred for CTC. Two consecutive kits, each with six negative 84 
windows, are required to “over-rule” an initial FOBt kit with 1-4 positive 85 
windows and obviate the need for further colonic testing. 86 
 87 
Data selection 88 
Test results within the BCSP are recorded on a database termed the “Bowel 89 
Cancer Screening System” (BCSS). Using anonymised data from BCSS, we 90 
identified screenees undergoing CTC as their first colonic investigation 91 
following a positive FOBt between April 2006 and December 2013 inclusive. 92 
For each screenee, the following were extracted: (a) age, (b) sex, (c) 93 
screening centre attended, (d) screening hub processing the FOBt kit, (e) 94 
number of positive FOBt windows on the initial test kit (and, if required, any 95 
subsequent follow-up test kits for those with a weak positive initial result), (f) 96 
CTC result (including size, location and morphology of any polyp(s) 97 
diagnosed), (g) result of subsequent endoscopy (again including size, location 98 
and morphology of polyp(s) found), (h) histological type and degree of 99 
dysplasia of resected polyp(s) and (i) staging information for confirmed 100 
carcinomas. A proportion of the patients we selected (2731 of 4601, 59.4%) 101 
have had their screening result published previously[11], although not 102 
stratified by FOBt status, which is the aim of the current study. 103 
 104 
Statistical analysis 105 
Data were collated using Microsoft Excel for Mac 2011 (Microsoft Corp, 106 
Redmond, WA, USA) and analyzed with R version 2.15.1 (R Foundation for 107 
Statistical Computing, Vienna, Austria). As histological endpoints, we 108 
analyzed the proportion of screenees with either histologically-confirmed 109 
cancer or advanced neoplasia according to the number of positive FOBt 110 
windows. For patients who returned more than one FOBt kit, we used the 111 
average number of positive windows across all FOBt kits, rounded to the 112 
nearest integer. Advanced neoplasia was defined as either CRC or an 113 
advanced adenoma (diameter ≥10mm, >20% villous features, and/or high-114 
grade dysplasia[5]). We also analyzed the proportion of screenees with CRC 115 
or any polyp ≥6mm suspected at CTC as a radiological endpoint, to account 116 
for the fact that not all screenees with abnormal CTC will undergo 117 
confirmatory colonoscopy. Analyses used the most advanced lesion in a given 118 
individual for the histological endpoints and the largest lesion for the 119 
radiological endpoint. Per-patient positive predictive value (PPV) of CTC for 120 
advanced neoplasia was calculated as the number of screenees with 121 
advanced neoplasia divided by the number in whom CTC diagnosed a ≥6mm 122 
lesion (on the basis that this is the standard referral threshold for colonoscopy 123 
in the BCSP); binomial 95% confidence intervals were derived using the 124 
Wilson method[12].  125 
 126 
To test whether detection rates were affected by the number of positive FOBt 127 
windows on the initial test kit, we performed multilevel binary logistic 128 
regression. The model accounted for the fact that screenees are grouped 129 
within screening centres, which themselves are grouped into screening hubs: 130 
Such clustering means there may be greater correlation between individuals 131 
within each group than those drawn from other groups. Separate models were 132 
built for the two histological endpoints and the radiological endpoint. The 133 
number of positive FOBt windows was entered as a screenee-level 134 
explanatory variable. For those screenees who required more than one FOBt 135 
kit (i.e. those testing weakly positive on their initial kit), we used the average 136 
number of positive FOBt windows across all screening kits returned, rounded 137 
to the nearest integer. Covariates were age and sex; screening centre and 138 
screening hub were entered as nested random effects terms[13]. Since the 139 
effect of FOBt positivity might not be linear, we also grouped the FOBt result 140 
into “weakly positive” (1-4 windows) and “strongly positive” (5-6 windows) as 141 
per current BCSP practice. Between-group comparisons were by the chi-142 
squared test or Mann-Whitney U-test, as appropriate. Results were 143 
considered significant at the 5% threshold. 144 
 145 
Results 146 
Screenee characteristics and FOBt results 147 
4601 screenees were included, 2109 females (45.8%) and 2492 males. Mean 148 
age was 66.7 years and was not significantly different between males (mean 149 
66.8 years) and females (mean 66.7 years, p=0.33). The majority of 150 
individuals who underwent CTC did so following a weakly positive result i.e. 1-151 
4 positive windows (3788 of 4601 screenees, 82.3%). The most common 152 
FOBt result precipitating CTC was 2 positive windows (1423 of 4601 153 
screenees, 30.9%) followed by a single positive window (1201 screenes, 154 
26.1%). The proportion of individuals undergoing CTC who had tested weakly 155 
positive showed no significant variation by gender (females: 1749 of 2109, 156 
82.9%; males: 2039 of 2492, 81.8%, p=0.35, Table 1). However, there was 157 
significant variation by screening hub, with the proportion of individuals testing 158 
weakly positive ranging from 78.9% (436 of 552 screenees) to 84.4% (1489 of 159 
1765, p<0.004). 160 
 161 
Variation in detection rates and PPV according to gender and FOBt 162 
result 163 
 164 
Histologically confirmed lesions  165 
Overall, 228 participants were diagnosed with cancer (5.0%) and 836 (18.2%) 166 
with either cancer or advanced adenoma (i.e. advanced neoplasia). Males 167 
had higher rates of cancer than females (155 of 2492 males, 6.2% vs 73 of 168 
2109 females, 3.5%; Χ2=17.9, p<0.001). Rates of advanced neoplasia were 169 
also significantly higher in males (both p<0.001, Table 2).  170 
 171 
Screenees with strongly positive FOBt had higher rates of cancer (78 of 813, 172 
9.6%) and advanced neoplasia (195 of 813, 24.0%) than those with weakly 173 
positive FOBt (cancer: 150 of 3788, 4.0%, Χ2=43.9, p<0.001; advanced 174 
neoplasia: 641 of 3788, 16.9%, Χ2=22.0, p<0.001; Table 2). Furthermore, 175 
there was a progressive increase in rates of cancer and advanced neoplasia 176 
as the number of positive FOBt windows increased (Table 2, Figure). These 177 
increases were statistically significant in the multilevel logistic regression 178 
model, with the odds ratio for the detection of advanced neoplasia being 1.17 179 
(95%CI 1.12-1.23, p<0.001); i.e. for each additional positive FOBt window, the 180 
odds of advanced neoplasia increased by 1.17. This effect was even stronger 181 
for the detection of colorectal cancer (OR 1.41, 95%CI 1.31-1.52, p<0.001). 182 
When considering FOBt as either weakly or strongly positive, the odds ratio 183 
for a strongly positive result (versus a weakly positive test) was 1.56 (95%CI 184 
1.29-1.87, p<0.0001) for advanced neoplasia and 2.56 (95%CI 2.21-2.96, 185 
p<0.0001) for colorectal cancer (Table 3). 186 
 187 
Radiologically detected abnormality 188 
Consistent with endpoints based on histological confirmation, the magnitude 189 
of FOBt positivity was significantly associated with the proportion of 190 
screenees harboring a ≥6mm lesion at CTC. Of the 813 individuals testing 191 
strongly positive, 243 (29.9%) had a ≥6mm lesion reported at CTC, compared 192 
to 883 of 3788 (23.3%) screenees who had tested weakly positive (Χ2=16.8, 193 
p<0.001). This difference remained significant in the regression models, 194 
whether FOBt status was treated as a linear variable (OR 1.16, 95%CI 1.11-195 
1.21, p<0.001) or categorized as strongly vs weakly positive (OR 1.42, 95%CI 196 
1.19-1.68, p<0.001, Table 3).    197 
 198 
Per-patient positive predictive value for advanced neoplasia (PPV) increased 199 
with stronger FOBt positivity. Overall, 1126 individuals had a ≥6mm lesion 200 
suspected at CTC and 836 had advanced neoplasia confirmed, a PPV of 201 
74.2% (95%CI 71.6-76.7%). This figure was significantly greater for those with 202 
a strongly positive FOBt result (195 advanced neoplasms from 243 positive 203 
CTC examinations, 80.2%, 95%CI 74.8-84.8%) than a weakly positive FOBt 204 
(641 advanced neoplasms from 883 positive CTC examinations, 72.6%, 205 
95%CI 70.0-75.4%, p=0.020, Figure). PPV was significantly higher in males 206 
(566 advanced neoplasms from 696 positive scans, 81.3%, 95%CI 78.3-84.0) 207 
than females (270 advanced neoplasms from 430 positive scans, 62.8%, 208 
95%CI 58.1-67.2%, p<0.001).   209 
 210 
Stage and location of cancers detected according to FOBt result 211 
Of the 228 cancers detected, both staging and FOBt results were available for 212 
164 (71.9%). Overall, the stage distribution of cancers detected following 213 
strongly- and weakly positive FOBt results were similar (Table 4). There was 214 
no evidence to suggest that Dukes’ stage was related to either the strength of 215 
test positivity (p=0.30) or the number of positive windows, although numbers 216 
in each category were small (Table 4). 217 
 218 
Locations of screen-detected cancers were available in 216 cases (95.6% of 219 
all cancers): 53 (23.5%) cancers were right-sided (proximal to the splenic 220 
flexure) and 163 (72.1%) were left-sided (at or distal to the splenic flexure). 221 
The median number of positive windows for patients with right-sided cancers 222 
was 4 out of a possible 6 (interquartile range 2 to 6); for those with left-sided 223 
cancers it was 3 (interquartile range 2 to 5); this difference was not statistically 224 
significant (p=0.20).   225 
 226 
Discussion 227 
 228 
CTC is intuitively attractive as an alternative to colonoscopy following positive 229 
FOBt, as it is highly sensitive and moderately specific for advanced 230 
neoplasia[10]. However, unselected use of CTC for FOBt-positive individuals 231 
(triaging those with normal results to routine screening, and those with 232 
positive CTC to colonoscopy) is unlikely to be cost-effective overall – the high 233 
prevalence of advanced neoplasia means that relatively few colonoscopies 234 
are avoided[14,15]. One cost-effectiveness study assessing CTC after 235 
positive FOBt[16] estimated only small savings (£776,283 over 10 years for 236 
100,000 screening invitations), which would be significantly outweighed by the 237 
costs of implementing such large-scale CTC infrastructure and training. 238 
Accordingly, CTC is generally reserved for individuals who are unable or 239 
unwilling to undergo total colonoscopy after positive FOBt[17]. 240 
 241 
We found that screenees with an average of only one positive FOBt window 242 
had relatively low rates of cancer (30 of 1201 individuals, 2.5%) and advanced 243 
neoplasia (174 of 1201, 14.5%). Recent colonoscopic data from the English 244 
BCSP has confirmed that low levels of FOBt positivity are also associated 245 
with lower detection rates of CRC, confirming our result using CTC[18]. So, 246 
although CTC is a relatively ineffective follow-up colonic test when employed 247 
for all FOBt-positive patients, it is possible that in the scenario of very weak 248 
positivity, CTC could become attractive because subsequent colonoscopic 249 
referral would be uncommon. CTC has been shown to boost compliance 250 
when targeted at FOBt-positive individuals who refuse colonoscopy[19] and in 251 
a randomised screening trial the compliance with CTC was significantly 252 
greater at 34% than that for colonoscopy (22%). In theory, such strategies 253 
might increase acceptability of the programme as a whole while also reducing 254 
overall costs. Health economic modeling studies or large prospective trials 255 
would be required to determine if substituting CTC for colonoscopy in 256 
screenes with small amounts of fecal occult blood is likely to be a net cost 257 
saving. 258 
 259 
The positive predictive value (PPV) of CTC for advanced neoplasia also 260 
increased in line with the number of positive FOBt windows, presumably partly 261 
because cancers and large adenomas bleed more[20] and partly because of 262 
higher disease prevalence. The anatomical location of detected cancers (i.e. 263 
just over 70% left-sided) was very similar to that described in prior reports of 264 
FOBt screening[4,21]. We found there was no difference in FOBt-positivity for 265 
left- and right-sided cancers, contrasting with a colonoscopy report 266 
documenting greater FOBt-positivity for right-sided cancers[9]. There are 267 
many possible explanations for this, including differences in populations under 268 
investigation, variable sensitivity of CTC and colonoscopy for right- and left-269 
sided lesions and underpowering due to the relatively small number of 270 
cancers included.  271 
 272 
The main limitation of our study is the fact that the true disease status of 273 
screenees who underwent CTC alone is unknown, since those having 274 
negative CTC were not investigated further. Theoretically, any bias might be 275 
greater in screenees with weakly positive FOBt results, since they may have 276 
more subtle, early stage lesions, perhaps more easily missed by CTC. 277 
However, since our findings are consistent with the colonoscopy literature[7], 278 
it seems unlikely that this is the sole explanation for detection varying 279 
according to FOBt positivity. Nonetheless, given prior concerns regarding the 280 
low detection rate of CTC compared to colonoscopy in the English BCSP[11], 281 
we would caution against concluding that the true rate of cancer in those with 282 
a single FOBt-positive window is as low as reported here: We do not know the 283 
rate of missed cancers. Even so, irrespective of the absolute rates of cancer 284 
and advanced neoplasia, the fact that there is a considerably lower 285 
prevalence of these significant lesions in screenees with small amounts of 286 
FOBt positivity supports the hypothesis that specifically targeting CTC to 287 
these individuals may be beneficial; this area should be the subject of further 288 
study. An additional limitation is sample size: Although this is (to our 289 
knowledge) the largest reported series of CTC in FOBt-positive patients, the 290 
absolute number of cancers is relatively small at 228, meaning differences in 291 
cancer location or stage according to number of positive FOBt windows may 292 
be undetected due to low statistical power. Although data regarding FOBt 293 
status and location of cancers were almost complete, cancer staging 294 
information was frequently missing from the BCSP database. Finally, as with 295 
any central database, conclusions are dependent on the accuracy of the data 296 
recorded: Although audit suggests accuracy of data input exceeds 90%, this 297 
may not be universal. 298 
 299 
In summary, we found that both the detection rate of CTC and its positive 300 
predictive value for advanced neoplasia increase in line with the number 301 
of positive windows in screenees testing positive for FOBt. In contrast, 302 
cancer stage and location were unrelated to the magnitude of FOBt 303 
positivity. Future studies should consider the effect on compliance and 304 
screening cost-effectiveness of CTC for lower risk patients, who are relatively 305 
less likely to harbor advanced neoplasia. 306 
307 
Figure Legend 308 
 309 
Figure: Left vertical axis: Percentage of screenees with cancer (triangle) or 310 
advanced neoplasia (circle). Right vertical axis: Postive predictive value of 311 
CTC for advanced neoplasia (diamond) 312 
313 
Acknowledgements 314 
 315 
Blinded 316 
 317 
318 
References 319 
 320 
1. Benson VS, Atkin WS, Green J, et al. Toward standardizing and reporting 321 
colorectal cancer screening indicators on an international level: The 322 
International Colorectal Cancer Screening Network. Int. J. Cancer 323 
2012;130(12):2961-73 doi: 10.1002/ijc.26310published Online First: Epub 324 
Date]|. 325 
2. Benson VS, Patnick J, Davies AK, et al. Colorectal cancer screening: a 326 
comparison of 35 initiatives in 17 countries. Int. J. Cancer 2008;122(6):1357-327 
67 doi: 10.1002/ijc.23273published Online First: Epub Date]|. 328 
3. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the 329 
faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007(1) 330 
doi: 10.1002/14651858.CD001216.pub2published Online First: Epub Date]|. 331 
4. Logan RFA, Patnick J, Nickerson C, et al. Outcomes of the Bowel Cancer 332 
Screening Programme (BCSP) in England after the first 1 million tests. Gut 333 
2012;61(10):1439-46 doi: 10.1136/gutjnl-2011-300843published Online First: 334 
Epub Date]|. 335 
5. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of 336 
screening. Gastrointestinal endoscopy clinics of North America 2002;12(1):1-337 
9  338 
6. Segnan N, Patnick J, von Karsa L. European guidelines for quality assurance in 339 
colorectal cancer screening and diagnosis. Secondary European guidelines 340 
for quality assurance in colorectal cancer screening and diagnosis.  2012 341 
2012. http://bookshop.europa.eu/en/european-guidelines-for-quality-342 
assurance-in-colorectal-cancer-screening-and-diagnosis-343 
pbND3210390/downloads/ND-32-10-390-EN-344 
C/ND3210390ENC_002.pdf;pgid=Iq1Ekni0.1lSR0OOK4MycO9B0000Z345 
33aOyCA;sid=c1hlNUHRPTVlORIfAvv7kiP0Pjt7R0YCdYs=?FileName346 
=ND3210390ENC_002.pdf&SKU=ND3210390ENC_PDF&CatalogueN347 
umber=ND-32-10-390-EN-C. 348 
7. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening 349 
on the incidence of colorectal cancer. N Engl J Med 2000;343(22):1603-7 doi: 350 
10.1056/NEJM200011303432203published Online First: Epub Date]|. 351 
8. Weller D, Moss S, Butler P, et al. English Pilot of Bowel Cancer Screening: an 352 
evaluation of the second round, 2006. 353 
9. Lee TJ, Clifford GM, Rajasekhar P, et al. High yield of colorectal neoplasia 354 
detected by colonoscopy following a positive faecal occult blood test in the 355 
NHS Bowel Cancer Screening Programme. J Med Screen 2011;18(2):82-6 356 
doi: 10.1258/jms.2011.011032published Online First: Epub Date]|. 357 
10. Plumb AA, Halligan S, Pendse DA, et al. Sensitivity and specificity of CT 358 
colonography for the detection of colonic neoplasia after positive faecal occult 359 
blood testing: systematic review and meta-analysis. Eur Radiol 2014 doi: 360 
10.1007/s00330-014-3106-0published Online First: Epub Date]|. 361 
11. Plumb AA, Halligan S, Nickerson C, et al. Use of CT colonography in the English 362 
Bowel Cancer Screening Programme. Gut 2013 doi: 10.1136/gutjnl-2013-363 
304697published Online First: Epub Date]|. 364 
12. Wilson E. Probable inference, the law of succession, and statistical inference. 365 
Journal of the American Statistical Association 1927;22(158):209-12  366 
13. lme4: Linear mixed-effects models using Eigen and S4 [program]. 1.0-5 version, 367 
2013. 368 
14. Liedenbaum MH, de Vries AH, van Rijn AF, et al. CT colonography with limited 369 
bowel preparation for the detection of colorectal neoplasia in an FOBT 370 
positive screening population. Abdominal Imaging 2010;35(6):661-68 doi: 371 
10.1007/s00261-009-9586-8published Online First: Epub Date]|. 372 
15. Liedenbaum MH, van Rijn AF, de Vries AH, et al. Using CT colonography as a 373 
triage technique after a positive faecal occult blood test in colorectal cancer 374 
screening. Gut 2009;58(9):1242-49 doi: 10.1136/gut.2009.176867published 375 
Online First: Epub Date]|. 376 
16. Sweet A, Lee D, Gairy K, et al. The impact of CT colonography for colorectal 377 
cancer screening on the UK NHS: costs, healthcare resources and health 378 
outcomes. Appl Health Econ Health Policy 2011;9(1):51-64 doi: 379 
10.2165/11588110-000000000-00000published Online First: Epub Date]|. 380 
17. Spada C, Stoker J, Alarcon O, et al. Clinical indications for computed 381 
tomographic colonography: European Society of Gastrointestinal Endoscopy 382 
(ESGE) and European Society of Gastrointestinal and Abdominal Radiology 383 
(ESGAR) Guideline. Endoscopy 2014;46(10):897-915 doi: 10.1055/s-0034-384 
1378092published Online First: Epub Date]|. 385 
18. Geraghty J, Butler P, Seaman H, et al. Optimising faecal occult blood 386 
screening:retrospective analysis of NHS Bowel Cancer Screening data to 387 
improve the screening algorithm. Br J Cancer 2014;111(11):2156-62 doi: 388 
10.1038/bjc.2014.480published Online First: Epub Date]|. 389 
19. Sali L, Grazzini G, Ventura L, et al. Computed tomographic colonography in 390 
subjects with positive faecal occult blood test refusing optical colonoscopy. 391 
Dig Liver Dis 2013;45(4):285-89 doi: 10.1016/j.dld.2012.11.008published 392 
Online First: Epub Date]|. 393 
20. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult 394 
blood test for colorectal neoplasia. Ann Intern Med 2007;146(4):244-55  395 
21. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial 396 
of faecal-occult-blood screening for colorectal cancer. Lancet 397 
1996;348(9040):1472-77 doi: 10.1016/S0140-6736(96)03386-7published 398 
Online First: Epub Date]|. 399 
 400 
 401 
Figure 1
Click here to download Figure: Figure 1.TIFF 
Table 1 – Demographics and overall FOBt result for included participants 
 
 
  Average number of positive FOBt windows Overall Total 
(any 
positive 
FOBt 
result) 
 
Number of 
screened 
individuals 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
Unknown 
Weakly 
positive 
(1-4 
windows) 
Strongly 
positive 
(5 or 6 
windows) 
 
Males 
(% of all 
males) 
 
 
667 
(26.8) 
 
734 
(29.5) 
 
394 
(15.8) 
 
162 
(6.5) 
 
210 
(8.4) 
 
317 
(12.7) 
 
8 
(0.32) 
 
2039 
(81.8) 
 
453 
(18.2) 
 
2492 
Females 
(% of all 
females) 
 
534 
(25.3) 
689 
(32.7) 
318 
(15.1) 
147 
(7.0) 
178 
(8.4) 
238 
(11.3) 
5 
(0.24) 
1749 
(82.9) 
360 
(17.1) 
2109 
 
Both 
sexes (% 
of total) 
 
1201 
(26.1) 
 
1423 
(30.9) 
 
712 
(15.5) 
 
309 
(6.7) 
 
388 
(8.4) 
 
555 
(12.1) 
 
13 
(0.28) 
 
3788 
(82.3) 
 
813 
(17.7) 
 
4601 
 
Tables
 
Table 2 – Detection rates of cancer, advanced neoplasia, ≥6mm 
radiologically-suspected lesions and per-patient positive predictive value 
(PPV) according to gender and average number of positive FOBt windows. 
Percentages use the number of screenees of the relevant gender and FOBt 
result as the denominator (see Table 1). 
 
 
 Average number of positive FOBt windows  Overall Total 
(any 
positive 
FOBt 
result) 
  
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
 
5 
 
 
6 
Weakly 
positive  
(1-4 
windows) 
Strongly 
positive 
(5 or 6 
windows) 
Both sexes          
Cancer (%) 30 
(2.5) 
 
37 
(2.6) 
30 
(4.2) 
34 
(11.0) 
38 
(9.8) 
58 
(10.5) 
150 
(4.0) 
78 
(9.6) 
228 
(5.0) 
Advanced 
neoplasia 
(%) 
 
174 
(14.5) 
206 
(14.5) 
146 
(20.5) 
78 
(25.2) 
96 
(24.7) 
135 
(24.3) 
641 
(16.9) 
195 
(24.0) 
836 
(18.2) 
Any 
radiology 
lesion 
≥6mm (%) 
 
226 
(18.8) 
309 
(21.7) 
197 
(27.7) 
110 
(35.6) 
109 
(28.1) 
174 
(31.4) 
883 
(23.3) 
243 
(29.9) 
1126 
(24.5) 
PPV for 
advanced 
neoplasia 
(95% CI) 
 
77.0 
(71.1-
82.0) 
66.7 
(61.2-
71.7) 
74.1 
(67.6-
80.0) 
70.9 
(61.8-
78.6) 
88.1 
(80.6-
92.9) 
77.6 
(70.8-
83.1) 
72.6 
(70.0-
75.4) 
80.2 
(74.8-
84.8) 
74.2 
(71.6-
76.7) 
Males          
Cancer (%) 24 
(3.6) 
 
19 
(2.6) 
19 
(4.8) 
22 
(13.6) 
24 
(11.4) 
46 
(14.5) 
98 
(4.8) 
57 
(12.6) 
155 
(6.2) 
Advanced 
neoplasia 
(%) 
 
125 
(18.7) 
133 
(18.1) 
97 
(24.6) 
45 
(27.8) 
63 
(30.0) 
102 
(32.2) 
426 
(20.9) 
140 
(30.9) 
566 
(22.7) 
Any 
radiology 
lesion 
≥6mm (%) 
 
140 
(21.0) 
182 
(24.8) 
128 
(32.5) 
59 
(36.4) 
68 
(32.4) 
118 
(37.2) 
536 
(26.3) 
160 
(35.3) 
696 
(27.9) 
PPV for 
advanced 
neoplasia 
(95%CI) 
 
89.3 
(83.1-
93.4) 
73.1 
(66.2-
79.0) 
75.8 
(67.7-
82.4) 
76.3 
(64.0-
85.3) 
92.6 
(83.9-
96.8) 
86.4 
(79.1-
91.5) 
79.5 
(75.9-
82.7) 
87.5 
(81.5-
91.8) 
81.3 
(78.3-
84.0) 
Females          
Cancer (%) 6 
(1.1) 
18 
(2.6) 
11 
(3.5) 
12 
(8.2) 
14 
(7.9) 
12 
(5.0) 
52 
(3.0) 
21 
(5.8) 
 
73 
(3.5) 
Advanced 
neoplasia 
(%) 
 
49 
(9.2) 
73 
(10.6) 
49 
(15.4) 
33 
(22.4) 
33 
(18.5) 
33 
(13.9) 
215 
(12.3) 
55 
(15.3) 
270 
(12.8) 
Any 86 127 69 51 41 56 347 83 430 
radiology 
lesion 
≥6mm (%) 
 
(16.1) (18.4) (21.7) (34.7) (23.0) (23.5) (19.8) (23.1) (20.4) 
PPV for 
advanced 
neoplasia 
(95%CI) 
 
57.0 
(46.4-
66.9) 
57.5 
(48.8-
65.7) 
71.0 
(59.4-
80.0) 
64.7 
(51.0-
76.4) 
80.5 
(66.0-
90.0) 
58.9 
(45.9-
70.8) 
62.0 
(56.7-
66.9) 
66.3 
(55.6-
75.5) 
62.8 
(58.1-
67.2) 
 
 
 
Table 3 – Factors associated with diagnosis of cancer, advanced neoplasia 
and any ≥6mm radiologically-diagnosed lesion following a positive FOBt 
result, derived by logistic regression and expressed as odds ratios.  
 
 
  Cancer 
(95%CI) 
p Advanced 
neoplasia 
(95%CI) 
p Any 
≥6mm 
radiology 
lesion 
(95%CI) 
 
p 
Considering the FOBt result as a linear variable (i.e. 1 to 6 positive windows) 
 
Age (per year 
increase) 
1.06 (1.03-
1.09) 
<0.001 1.03 (1.01-
1.05) 
<0.001 1.04 (1.03-
1.06 
<0.001 
Male sex (vs 
female) 
 
1.82 (1.37-
2.43) 
<0.001 2.00 (1.71-
2.35) 
<0.001 1.52 (1.32-
1.74) 
<0.001 
Number of 
positive FOBt 
windows (per 
additional positive 
window) 
 
1.41 (1.31-
1.52) 
<0.001 1.17 (1.12-
1.23) 
<0.001 1.16 (1.11-
1.21) 
<0.001 
Considering the FOBt result as a binary variable (i.e. weakly or strongly positive) 
 
Age (per year 
increase) 
1.06 (1.03-
1.09) 
 
<0.001 1.03 (1.01-
1.05) 
<0.001 1.04 (1.03-
1.06) 
<0.001 
Male sex (vs 
female) 
1.83 (1.37-
2.43) 
 
<0.001 2.00 (1.70-
2.34) 
<0.001 1.52 (1.32-
1.74) 
<0.001 
Strongly positive 
FOBt result (vs 
weakly positive) 
 
2.56 (2.21-
2.96) 
<0.001 1.56 (1.29-
1.87) 
<0.001 1.42 (1.19-
1.68) 
<0.001 
 
Table 4 – Number (percentage) of patients with cancer of each Duke’s stage, 
according to degree of FOBt positivity. Percentages use the total number of 
patients with a given FOBt result as the denominator. 
 
  
 Average number of positive FOBt windows Overall FOBt result Total 
Duke’s 
stage 
1 2 3 4 5 6 Weakly 
positive 
Strongly 
positive 
 
A 
(%) 
9 
(26.5) 
9 
(24.3) 
6 
(20.0) 
9 
(26.5) 
11 
(28.9) 
8 
(13.8) 
37 
(24.7) 
15 
(19.2) 
52 
(22.8) 
B 
(%) 
7 
(20.6) 
8 
(21.6) 
7 
(23.3) 
9 
(26.5) 
9 
(23.7) 
21 
(36.2) 
36 
(24.0) 
25 
(32.1) 
61 
(26.8) 
C 
(%) 
3 
(8.8) 
8 
(21.6) 
6 
(20.0) 
7 
(20.6) 
4 
(11.5) 
12 
(20.7) 
26 
(17.3) 
14 
(17.9) 
40 
(17.5) 
D 
(%) 
2 
(5.9) 
0 
(0.0) 
0 
(0.0) 
2 
(5.9) 
2 
(5.3) 
5 
(8.6) 
5 
(3.3) 
6 
(7.7) 
11 
(4.8) 
Missing 
(%) 
10 
(29.4) 
12 
(32.4) 
11 
(36.7) 
7 
(20.6) 
12 
(31.6) 
12 
(20.7) 
46 
(30.7) 
18 
(23.1) 
64 
(28.1) 
Total 
(%) 
31 
(100) 
37 
(100) 
30 
(100) 
34 
(100) 
38 
(100) 
58 
(100) 
150 
(100) 
78 
(100) 
228 
(100) 
 
 
Highlights: 
1. Detection rates at CTC increase with higher levels of fecal occult blood 
(FOB) 
2. Positive predictive value of CTC increases with greater FOB positivity 
3. Stage and location of cancers are not affected by magnitude of FOB 
positivity. 
4. CTC may be valuable for otherwise low-risk patients with small amounts of 
FOB. 
 
Highlights
